Arachidonate 5-lipoxygenase-activating protein · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Arachidonate 5-lipoxygenase-activating protein shows late clinical disease relevance led by acute coronary syndrome. 3 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P20292. Start with acute coronary syndrome, then reuse UniProt P20292 as the stable protein anchor across project notes and exports.
Start with acute coronary syndrome, then reuse UniProt P20292 as the stable protein anchor across project notes and exports.
Arachidonate 5-lipoxygenase-activating protein shows late clinical disease relevance led by acute coronary syndrome. 3 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with acute coronary syndrome because it currently carries late clinical support. Linked drugs include VELIFLAPON. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyArachidonate 5-lipoxygenase-activating protein
Review this target as Arachidonate 5-lipoxygenase-activating protein, mapped to UniProt P20292. Sequence length is 161 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Arachidonate 5-lipoxygenase-activating protein as ChEMBL target CHEMBL4550, mapped to UniProt P20292. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Arachidonate 5-lipoxygenase-activating protein is the right protein anchor across sources, using UniProt P20292 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why acute coronary syndrome is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Arachidonate 5-lipoxygenase-activating protein |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P20292 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Arachidonate 5-lipoxygenase-activating protein |
| UniProt Accession | P20292 |
| Component Type | Protein |
| Sequence Length | 161 aa |
Arachidonate 5-lipoxygenase-activating protein
Review this target as Arachidonate 5-lipoxygenase-activating protein, mapped to UniProt P20292. Sequence length is 161 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Arachidonate 5-lipoxygenase-activating protein shows late clinical disease relevance led by acute coronary syndrome. 3 more disease programs remain visible in the same review block.
Start review with acute coronary syndrome because it currently carries late clinical support. Linked drugs include VELIFLAPON. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL1922653 | 9.52 | IC50 | 0.3 | Preclinical |
| CHEMBL3667000 | 9.47 | Ki | 0.34 | Preclinical |
| CHEMBL1922655 | 9.4 | IC50 | 0.4 | Preclinical |
| CHEMBL1922656 | 9.4 | IC50 | 0.4 | Preclinical |
| CHEMBL1922657 | 9.4 | IC50 | 0.4 | Preclinical |
| CHEMBL1922663 | 9.4 | IC50 | 0.4 | Preclinical |
| CHEMBL3704300 | 9.4 | Ki | 0.4 | Preclinical |
| CHEMBL3700843 | 9.4 | Ki | 0.4 | Preclinical |
| CHEMBL3667001 | 9.38 | Ki | 0.42 | Preclinical |
| CHEMBL3666967 | 9.33 | Ki | 0.47 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 45 | 471 | 7.1 |
| cell-based format | 25 | 253 | 7.8 |
| assay format | 17 | 1,681 | 7.5 |
| tissue-based format | 10 | 75 | 6.4 |
| cell membrane format | 3 | 35 | 7.7 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 3 | 1 | 7.3 |